Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

Rangaprasad Sarangarajan1 & Robert Winn2 & Michael A. Kiebish1 & Chas Bountra3 & Elder Granger1 & Niven R. Narain1

Received: 2 May 2020 / Revised: 5 August 2020 / Accepted: 24 August 2020 / Published online: 8 September 2020
© The Author(s) 2020

Abstract

Rationale Hypertension, obesity and diabetes are major risk factors associated with morbidities underlying COVID-19 infections. Regression analysis correlated presence of ACE insertion/deletion (I/D) polymorphism to COVID-19 incidence and mortality. Furthermore, COVID-19 prevalence correlated to allele frequency of angiotensin-converting enzyme (ACE) deletion (D) polymorphism within the European population.

Objective Homozygous ACE deletion polymorphism is associated with increase in ACE and angiotensin II (Ang-II), sustained levels can result in inflammation, fibrosis and organ damage. The ACE DD polymorphism is also associated with hypertension, acute respiratory distress and diabetic nephropathy, all considered high risk for COVID-19 infection and outcomes. The study objective was to describe a biological framework associating ethnic prevalence of ACE deletion polymorphism to COVID-19 comorbidities providing rationale for therapeutic utility of ACE-I/ARBs to improve outcomes.

Method and Results The Allele Frequency Database (ALFRED) was queried for frequency of rs4646994 representing ACE I/D polymorphism. In a total of 349 worldwide population samples, frequency of ACE D allele was higher in European, Asian, and Africans cohorts. In the USA, the frequency of ACE D allele was higher in non-Hispanic Black compared with non-Hispanic White and Mexican Americans.

Conclusion COVID-19 binding mediated reduction/inactivation of ACE-II can increase ACE/Ang-II signalling pathway and related pathologies. The presence of ACE DD polymorphism with COVID-19 infection likely augments ACE/Ang-II activities, increasing severity of COVID-19 morbidities and impacts outcomes. Thus, ethnic prevalence of ACE DD polymorphism can explain in part the severity of COVID-19 morbidity providing rationale for the use of ACE-I/ARBs to improve outcomes.

Keywords Angiotensin · ACE · Polymorphism · Ethnic · COVID-19

Introduction

The SARS-CoV-19 (COVID-19) infection has infected in excess of seventeen million individuals around the globe and is designated as a pandemic by the World Health Organization.

The global efforts are focused on understanding the disease onset, progression and to identify causal linkage for differences in observed outcomes among the affected population and within specific demographics. Despite worldwide spread of the COVID-19 infections, European countries and the USA appear to have experienced higher incidence and mortality rates [1–3]. Hypertension, obesity, and diabetes were identified as the most common comorbidities associated with COVID-19 infection; higher severity of disease and mortality was generally reported in the elderly (> 50 years) population.

Angiotensin-converting enzyme 2 (ACE2) is the predominant receptor for SARS-CoV viral entry and infection, resulting in the reduction of expression of ACE2 [4, 5]. ACE2 is an enzyme component of the renin-angiotensin system (RAS), a complex integrated network of peptides-enzyme
combination, generating catalytically active peptides with prominent influence on the vascular, renal, cardiac, and immune system [6]. In this report, we describe a framework of the pathophysiological consequence of COVID-19-induced reduction in ACE2, i.e., overactivation of the RAS pathway with the potential to have deleterious effect on organ functions including the lungs, kidneys, heart, and immune system. The deleterious activities of RAS within the COVID-19-infected cohorts can be further amplified by the presence of genetic polymorphism in the angiotensin-converting enzyme (ACE). Increased prevalence in frequency of the ACE polymorphism within ethnic groups, in part, is likely responsible for the observed severity of COVID-19 comorbidities and mortality in this population. This is substantiated by recent regression analysis linking presence of ACE-1 I/D (insertion/deletion) polymorphism with incidence and mortality with COVID-19 infection [7].

Renin-Angiotensin System: ACE, Ang-II, and Inflammation

The RAS system has a prominent role in the regulation of vascular dynamics; its components directly or indirectly influence functions of the lung, heart, kidney, brain and the immune system [6]. In addition to central RAS components, i.e., renin (kidney), ACE (lungs), and angiotensinogen (liver), tissue-specific localized systems including the kidney, heart, and lungs have been identified [6, 8]. Within RAS, the canonical angiotensin-converting enzyme (ACE) is responsible for conversion of angiotensin-1 (Ang-I) to angiotensin-2 (Ang-II) (Fig. 1a). Subsequently, Ang-II mediates its effects through activation of AT-1 and AT-2 receptors, resulting in distinct intracellular signalling pathways [9–11]. Activation of AT-1 receptors is associated with the well-characterized physiological actions of Ang-II in various organs including the lung, heart, kidney, and the vascular system [10].

In addition to its hemodynamic effect, Ang-II has significant pro-inflammatory effects, promoting generation of reactive oxygen species (ROS), cell proliferation, extracellular matrix remodelling, and regulation of gene expression via signalling pathways leading to tissue injury [8, 12]. Ang-II promotes expression of pro-inflammatory chemokines in the kidneys, heart, and vasculature to induce inflammation [13]. Several studies have characterized key inflammatory processes influenced by Ang-II on macrophages, dendritic cells, and mesangial cells resulting in mobilization and activation of cytokines, chemokines, and pro-inflammatory factors resulting in tissue damage and progressive organ failure [14]. Due to profound influence of Ang-II signalling pathways that are predominantly adverse when unmitigated, the potency of Ang-II is tightly regulated via proteolytic activities of enzymes to generate various angiotensin peptide fragments with physiological activities different from Ang-II [14] (Fig. 1a). ACE2 is an enzyme component of RAS, with proteolytic activities different from the canonical ACE. ACE2 is responsible for cleaving angiotensin I to Ang (1–9) and angiotensin-2 to Ang (1–7) peptides respectively (Fig. 1), of which the latter is a potent vasodilator [15, 16]. Several studies support a major role for Ang (1–7) in providing the counterbalance to the physiological effects of Ang-II [17–19]. Thus, the pro-inflammatory effects of ACE/Ang-II axis are balanced by activation of anti-inflammatory pathways by ACE2 and other systems.

ACE Insertion/Deletion (ID) Polymorphisms: Prevalence

Two recent publications reported that ACE insertion/deletion polymorphism correlated to infectivity and mortality associated with COVID-19 infections [7, 20]. In humans, the gene encoding ACE is located on chromosome 17 and exhibits an insertion/deletion polymorphism that is characterized by an insertion (allele I) or deletion (allele D) of a 287 base pair marker in intron 16 that results in three different genotypes, i.e. DD or II homozygotes or ID heterozygotes. It is reported that the deletion (D) allele occurs in 55% of the population and associated with increased ACE activity, implicating the presence of D allele with disease pathologies associated with RAS activity [21].

The Allele Frequency Database (ALFRED; https://alfred.med.yale.edu/alfred/index.asp; RRID:SCR_001730) was queried for frequency of rs4646994 representing ACE I/D polymorphism, one of the best studies of all ACE polymorphisms. The allelic frequencies of the insertion (I, +) and deletion (allele D) of a 287 base pair marker in intron 16 that results in three different genotypes, i.e. DD or II homozygotes or ID heterozygotes. It is reported that the deletion (D) allele occurs in 55% of the population and associated with increased ACE activity, implicating the presence of D allele with disease pathologies associated with RAS activity [21].
has higher frequency of the D allele (Table 2) compared with non-Hispanic White and Mexican American population [23]. The frequency of the D allele was increased compared with the I allele within the Middle Eastern population with higher values observed in both Arab and Saudi Arabia sample populations. In contrast to Africa and Middle East, increased frequency of the I allele was observed in sample populations from Asia (India, Pakistan Nepalese, Tajik regions and Sri Lanka), Oceania (New Zealand, Papua New Guinea and Micronesia), East Asia (China, Japan, Korea, Taiwan, Cambodia, Vietnam, Philippines and Malaysia) and South American countries.
ACE Deletion (D) Polymorphism and Disease—Increased Susceptibility and Severity to Co-morbidities Associated with COVID-19

Although the ACE I/D polymorphism is located in a non-coding region, its presence is directly linked to regulation of renin-angiotensin system and associated pathological conditions. A positive association between D allele and high blood pressure, atherosclerosis, coronary artery disease, stroke, diabetic nephropathy and Alzheimer’s disease has been extensively reviewed [24]. The molecular underpinning of these diseases is multi-factorial and complex, and the presence of the ACE deletion polymorphism may contribute to influence disease pathology. Indeed, to date, there is distinct lack of consensus studies linking the presence of ACE deletion polymorphism to disease causality. Nevertheless, the increase in levels of ACE in individuals with the ID and DD genotypes and potential augmentation of the RAS system and associated signalling cascades can influence pathways to influence disease pathology [25] (Fig. 1b). Indeed, increased levels of ACE and Ang-II have been implicated in the pathophysiology of

Table 1  Prevalence of ACE insertion/deletion polymorphism: the Allele Frequency Database (ALFRED) was queried for identifying population frequency of the ACE insertion/deletion polymorphism among geographical locations. From a total of 349 population samples, the average frequencies of the insertion and deletion allele for ACE were calculated for the different geographical locations. The table provides the population sample size and frequency (italicized) and the breakdown of the frequency of the insertion and deletion allele within specific ethnic groups of interest within the population

| Sample size (N) | Insertion | Deletion |
|----------------|-----------|----------|
| Europe         | 16,220    | 0.412    | 0.588    |
| Abazians       | 24        | 0.000    | 1.000    |
| Canarian       | 1358      | 0.375    | 0.625    |
| English        | 924       | 0.454    | 0.546    |
| French         | 2234      | 0.423    | 0.578    |
| Irish          | 226       | 0.429    | 0.571    |
| Italians       | 222       | 0.342    | 0.658    |
| Jews, Ashkenazi| 154       | 0.340    | 0.660    |
| Africa         | 2126      | 0.340    | 0.660    |
| Pygmies        | 68        | 0.221    | 0.779    |
| Jews, Ethiopian| 64        | 0.203    | 0.797    |
| Moroccans      | 106       | 0.292    | 0.708    |
| Nigerians      | 22        | 0.273    | 0.727    |
| Tunisian       | 200       | 0.325    | 0.675    |
| Middle East    | 1714      | 0.360    | 0.640    |
| Arabs          | 100       | 0.290    | 0.710    |
| Saudi          | 540       | 0.275    | 0.725    |
| Asia           | 7380      | 0.585    | 0.414    |
| Oceania        | 1444      | 0.684    | 0.315    |
| East Asia      | 3182      | 0.627    | 0.372    |
| South America  | 2458      | 0.706    | 0.293    |

Table 2  ACE polymorphism allele and genotype frequencies: the prevalence of 289-bp Alu insertion/deletion in intron 16 of ACE gene corresponding to rs4646994 within the non-Hispanic White and non-Hispanic Black population is described. (Information modified from source provided by Office of Science (OS), Office of Genomics and Precision Public Health, CDC 2009; complete data is available at https://www.cdc.gov/genomics/population/genvar/frequencies/ace.htm)

| Gene variant | Race/ethnicity | Allele % | Allele % (95% CI) | Chi-square | HW p Value |
|--------------|---------------|----------|-------------------|------------|------------|
|              |               | Allele % | Allele % (95% CI) | p Value    | p Value    |
|              |               | D        | I                 | DD         | DI         | II         |              |              |
| rs4646994    | Non-Hispanic White | 54.6    | 45.4              | 28.8 (25.9,31.8) | 51.6 (47.8,55.3) | 19.6 (17.7, 21.8) | < 0.001     | 0.11         |              |              |
|              | Non-Hispanic Black | 58.7    | 41.3              | 33.8 (31.5,36.3) | 49.8 (47.3,52.2) | 16.4 (14.6,18.5) | < 0.001     | 0.1          |              |              |
lung (pulmonary hypertension, pulmonary fibrosis, acute lung injury and acute respiratory distress syndrome [26, 27]) and kidney disease (chronic kidney disease, diabetic nephropathy [28, 29]). In the African American population, the deletion polymorphism is associated with increase in systolic blood pressure, hypertension and altered vascular reactivity with potential impact on cardiovascular disease [30–32].

A subset of individuals with a positive diagnosis of COVID-19 infection have rapid progression of lung dysfunction leading to acute respiratory distress with potential need for ventilatory support [2, 3]. Presence of ACE insertion/deletion (I/D) polymorphism is associated with susceptibility and is an independent risk factor for mortality in patients with acute respiratory distress syndrome (ARDS) [33, 34]. Of the three ACE polymorphisms, there is positive association with frequency of the DD allele and incidence of ARDS, increased fatality and a prognostic factor of outcomes [35–37]. Further, the DD genotype is usually associated with higher ACE levels relative to other genotypes and with increased mortality in acute lung injury (ALI)/ARDS patients [38, 39]. Elevated levels of ACE have been observed in the bronchoalveolar fluid of individuals with ARDS [28]. Although decreases in circulating ACE have been reported in ARDS patients [40], this might be a consequence of the progressive damage to lung tissue as increased levels of ACE are evident in the bronchoalveolar fluids of individual with ARDS [40]. The positive relationship between DD genotype and ALI/ARDS and the corresponding increase in ACE levels suggest the potential involvement of increased Ang-II in the etiopathology of ARDS. During the avian (H7N9) flu infections, approximately 70% of patients developed ARDS [41]. In a subset of infected patients, increase in plasma Ang-II levels was linked to severity and fatal outcomes [41].

Within the COVID-19-infected population, there is increased incidence of kidney injury associated with higher mortality rates [42, 43]. Chronic kidney disease (CKD) is associated with severity of COVID-19 infection [44]. Interestingly, both ACE and ACE2 expressions in the kidneys are predominant in the proximal tubules with minor expression in the glomerular apparatus [45]. The balance between Ang-II and Ang (1–7) affects renal RAS to maintain balance of kidney functions; imbalance of the ratio results in kidney disease [46–48]. Chronic kidney disease is characterized by decreases in cardiac and renal ACE2 in human [49]. Diabetic nephropathy (a CKD) is characterized by decrease in ACE2, increased ACE and Ang-II-mediated tubular and glomerular damage as a result of renal RAS activation [28, 29]. Based on these studies, the ability of COVID-19 to bind and decrease ACE2 in target tissues is most likely responsible for the observed increase in blood urea nitrogen, proteinuria and hematuria associated with kidney damage [49]. Thus, COVID-19-associated decrease in ACE2 most likely results in disruption of the ACE/ACE2 balance in the kidney leading to sustained activation of ACE and Ang-II activities and kidney damage.

ACE insertion/deletion polymorphism is also associated with diabetic kidney disease, the frequency of DD and ID genotype distribution being higher compared with non-diabetic kidney disease cohorts, leading to functional decline [50, 51]. The above observations suggest that presence of the DD genotype of ACE in patients with COVID-19 infection may be associated with severe respiratory distress compared with the other genotypes.

Multiple studies have reported on the prevalence of ACE I/D polymorphism, specifically the ID and DD polymorphism in increasing levels of ACE and Ang-II, which could in part influence susceptibility to underlying pathologies considered high risk for COVID-19 infections, progressive organ dysfunction and poor outcomes. Thus, presence of ID and DD polymorphism by itself is a potential underlying risk factor associated with severity and outcomes in individuals with positive diagnosis of COVID-19 infection [20, 21].

**ACE-2 Inhibition by COVID-19: Increased RAS Activity**

The proteolytic cleavage of Ang-II by ACE2 to generate Ang (1–7) represents a major event leading to the physiological inactivation of Ang-II function. Thus, in patients with active COVID-19 infections, decrease in ACE2 expression/activity should most likely lead to sustained ACE-mediated generation of Ang-II and downstream signalling deleterious to organ functions including that of lung, kidney and heart [52]. Although the status of circulating and lung ACE levels in COVID-19 patients is unclear, the ability of SARS-Cov-2 binding specifically to ACE2 decreases its expression and activity suggesting upregulation of ACE/Ang-II-mediated activities. This is consistent with the observation that knockdown of ACE2 is associated with severe ARDS in multiple rodent models compared with corresponding wild-type controls [18]. Loss of ACE2 expression in mutant mice is associated with worse lung function and characterized by increases in vascular permeability, lung oedema and neutrophil accumulation [18]. Interestingly, reduced plasma levels of ACE2 are also observed within populations of African descent including African Americans, specifically in individuals with pre-hypertensive status, diabetes and renal disease [53, 54].

Administration of a catalytically active recombinant ACE2 protein improved symptoms of acute lung injury in ACE2 knockout and wild-type mice [55]. In a pilot clinical investigation, administration of recombinant human ACE2 (APN311) in patients with acute respiratory distress was associated with rapid decrease in Ang-II level and did not significantly influence oxygenation indices in the treated population compared with placebo-controlled group [56]. The recombinant human ACE2 is undergoing renewed clinical testing in the COVID-19 patient population to investigate clinical outcomes [52].
ACE2 inhibition by COVID-19 Plus ACE D Polymorphism: Synergized RAS—Rationale for Use of ACE-I and ARBs in Clinical Management

SARS-CoV-2 binding to ACE2 results in reduction of protein expression, activity and ability to generate anti-inflammatory signalling, all of which contribute to a pro-inflammatory phenotype due to presence of ACE activity and Ang-II signalling (Fig. 1c). Presence of ACE D polymorphism increases ACE levels and Ang-II leading to pro-inflammatory phenotype and is associated with disease susceptibilities considered high risk for COVID-19 infections. Recently, it was proposed that reduced plasma levels of ACE2 in individuals of African descent most likely lowers potential for COVID-19 infection [57]; the overall outcomes in individuals with presence of ACE deletion polymorphism after infection with COVID-19 most likely leads to exacerbation of comorbidities and overall deleterious outcomes. Based on the described biological consequence of COVID-19 infections on the RAS system, treatment with ACE-I and ARBs should be associated with improved outcomes within the overall COVID-19 patient cohorts. Indeed, several meta-analyses provide preliminary support for the potential benefits of the use of ACE-I/ARBs in management of COVID-19 infections.

In a multicenter study of 1128 adult patients with hypertension with positive COVID-19 diagnosis, in-patient use of ACE-I/ARB was associated with reduced risk of mortality from all causes when compared with patients not treated with the medications [58]. Recent publications further highlight the use of ACE-I and ARBs in providing cardiovascular and renal benefits to patients with COVID-19 diagnosis [59, 60]. In a meta-analysis, patients treated with ACE-I/ARB had 44% reduction in odds of developing severe disease and death compared with patients not treated with ACE-I/ARBs [61]. These studies provide rationale for investigation into the utility of ACE-I/ARBs in the ethnic population with known prevalence of ACE deletion polymorphisms in an effort to mitigate severity and improve outcomes in response to COVID-19 infections.

Use of ACE-I/ARBs in Ethnic Population with Increased Prevalence of ACE D Polymorphism for Management of COVID-19

ACE is a multi-functional, relatively non-specific peptidase enzyme with a wide range of substrate specificities that impact physiological pathways in influencing blood pressure, haematopoiesis, hormone regulation, renal function and immune responses. The specificity of hypertension and cardiovascular disease as underlying causes for severity of COVID-19 infection, the inherent role of ACE-mediated generation of Ang-II and downstream signalling to potentially exacerbate inflammation and organ damage along with genotypic impact on ACE status provide compelling support of the use of ACE-I and ARBs in the clinical management of patient with positive diagnosis of COVID-19.

The biological impact of the presence of deletion polymorphism of ACE in individuals with COVID-19 infection provides a significant rationale for serious consideration of short-term use of ACE-I and/or ARBs in patients without underlying issues with blood pressure or cardiovascular disorder. The guidance statement issued by the Heart Failure Society of America (HFSA), the American College of Cardiology (ACC) and American Heart Associated (AHA) states that in the absence of favourable or detrimental effects of ACE-I and ARBs in the COVID-19 setting, the recommendation is to not arbitrarily or pre-emptively discontinue these agents in patients currently on the medication as standard of care (acc.org). Indeed, both ACE-I and ARBs have been extensively used in conditions ranging from hypertension, congestive heart failure, prevention of kidney failure and other indications. Both classes of drugs have extensive use history, understanding of safety, tolerability, efficacy, adverse events profile and drug interactions. The significant genetic, scientific and clinical data supporting a potential role for increased ACE levels and associated Ang-II effect in target organs provides compelling argument for use of ACE-I and ARBs in the clinical management of patients with COVID-19 infections to improve outcomes. High salt sensitivity–associated low plasma renin activities are responsible for the attenuated blood pressure–lowering response of ACE-I in the African American population [62]. However, this particular phenomenon might be of potential advantage in dosing and management of severity of COVID-19-associated morbidities in African American and other ethnic populations with ACE deletion polymorphism.

In summary, this study describes the biological relevance of genetic polymorphism of ACE deletion with higher prevalence in certain ethnic populations including African Americans in context of COVID-19 infection and rationale for the use of ACE-I/ARBs for therapeutic management of severity of morbidity and improving outcomes associated with COVID-19.

Author Contributions RS is responsible for concept; MAK, CB, EG, NRN contributed to the structure and content of the manuscript.

Funding Mr. Carl E. Berg supported this work.

Data Availability All data obtained from public resources and referenced in the manuscript.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.
References

1. Saglietto A, D’Ascenzo F, Zoccai GB, De Ferrari GM. COVID-19 in Europe: the Italian lesson. Lancet. 2020;395(10230):1110–1. https://doi.org/10.1016/S0140-6736(20)30690-5.

2. Coronavirus disease 2019 (COVID19) in the EU/EEA and the UK – ninth update, 23 April, 2020 Stockholm: ECDC; 2020.

3. Garg S, Kim L, Whitaker M, O’Halloran A, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 States, March 1–30, 2020. Morbidity Mortal Weekly Rep. 2020;69(15):458–64.

4. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1–10.

5. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–63.

6. Kuriyama S, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behaviour of the renin-angiotensin systems components. Int J Biochem Cell Biol. 2005;37(7):1357–67.

7. Kenyon C. ACE-1 I/D polymorphism associated with COVID-19 incidence and mortality: an ecological study. https://doi.org/10.20944/preprints202004.0262.v1.

8. Fyhrquist F, Saijonmaa O. Renin – angiotensin system revisited. J Intern Med. 2008;264(3):224–36.

9. Lindberg BF, Gyllstedt E, Andersson KE. Conversion of angiotensin II by chymase activity in human pulmonary membranes. Peptides. 1997;18(6):847–53.

10. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334(25):1649–54.

11. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Inflammation and angiotensin II. Int J Biochem. 2000;32(1):33238.

12. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985–91.

13. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:851–900.

14. Bennigni A, Paola C, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247–57.

15. Donoghue M, Hsieh F, Barosas E, Godbout K, et al. A novel angiotensin-converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87:E1–9.

16. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238–43.

17. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung disease. Curr Opin Pharmacol. 2006;6:271–6.

18. Imai Y, Kuba K, Rao S, Yi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–6.

19. Abdul-Hafez A, Mohamed T, Omar H, Shemis M, et al. The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis. J Lung Pulm Repair Res. 2018;5(1):1–12.

20. Delanghe JR, Speeckaert MM, De Buyzere ML. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 2020;505:192–3.

21. Gard PR. Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet. 2010;1(2):145–57.

22. Staessen JA, Ginocchio G, Wang JG, Saavedra AP, et al. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk. 1997;4:401–22.

23. Ned RM, Yesupriya A, Imperatore G, Smelser DT, Moonesinghe R, Chang MH, et al. The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J Hypertens. 2012;25(2):209–15.

24. Sayed-Tahatabaei FA, Isaacs OA, van Duijn CM, Witteman JCM. ACE polymorphisms. Circ Res. 2006;98:1123–33.

25. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corpol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343–6.

26. Wang J, Chen L, Chen B, Melton A, et al. Chronic activation of the renin-angiotensin system induces lung fibrosis. Sci Rep. 2015;5:1–11.

27. Idell S, Kueppers F, Lippman M, Rosen H, et al. Angiotensin converting enzyme in bronchoalveolar lavage in ARDS. Chest. 1987;91(1):52–6.

28. Mizuiri S, Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol. 2015;4(1):74–82.

29. Mizuiri S, Hemmi H, Arita M, Ohashi Y, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008;51(4):613–23.

30. Gainer JV, Stein CM, Neal T, Vaughan DE, Brown NJ. Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension. 2001;37:46–51.

31. Duru K, Farrow S, Wang J-M, Lockette W, Kurtz T. Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African Americans with hypertension. Am J Hypertens. 1994;7(8):759–62.

32. Asamoah A, Yanamandra K, Thurmon TF, Richter R, Green R, Lakin T, et al. A deletion in the angiotensin converting enzyme (ACE) gene is common among African Americans with essential hypertension. Pediatr Res. 1996;39:142.

33. Deng X, Zhang S, Jin K, Li L, Gu W, Liu M, et al. Angiotensin converting enzyme I/D polymorphism and acute respiratory syndrome. J Renin-Angiotensin-Aldosterone Syst. 2015;16(4):780–6.

34. Adamzik M, Frey U, Sist S, Kenemeyer L, Beiderlinden M, Peters J, et al. ACE I/D but not AGT (–6) A/G polymorphism is a risk factor for mortality in ARDS. Eur Respir J. 2007;29:482–8.

35. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002;166:646–50.
36. Lu X-M, Chen G-J, Yang Y, H-B Q. Angiotensin-converting enzyme polymorphism affects outcome of local Chinese with acute lung injury. Respir Med. 2011;105:1485–90.

37. Jih-Shuin J, Chong-Jen Y, Hao-Chien W, Kuan-Yu C, et al. Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med. 2006;34(4):1001–6.

38. Tsantes AE, Kopterides P, Bonovas S, Bagos PG, Antonakos G, Nikolopoulos GK, et al. Effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome. Minerva Anestesiol. 2013;79:861–70.

39. Burgis JJ, Den Uil CA. ACE insertion/deletion polymorphism in sepsis and acute respiratory distress syndrome. Intensive Care Med. 2008;34:1733.

40. Fourrier F, Chopin C, Wallaert B, Mazurier C, et al. Compared evolution of plasma fibronectin and angiotensin-converting enzyme levels in septic ARDS. Chest. 1985;87:191–5.

41. Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, et al. Angiotensin II gene polymorphism with diabetic kidney disease. Nephrol Dial Transplant. 2012;27:1793–800.

42. Bernardi S, Toffoli B, Zennaro C, Tikellis C, Monticone S, Losurdo P, et al. High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. Nephrol Dial Transplant. 2012;27:1793–800.

43. Soler MJ, Wysocki J, Balle D. ACE2 alterations in kidney disease. Crit Care Med. 2020;48:1817–25.

44. Wakahara S, Kojohita T, Mizuno S, Motomura M, Aoyama C, Makino Y, et al. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinol Metabol Res. 2007;41:2453–7.

45. Roberts MA, Velkoska E, Ierino FL, Burrell LM. Angiotensin converting enzyme 2 activity in patients with chronic kidney disease. Nephrol Dial Transplant. 2013;28:2287–94.

46. Wang Y, Peng W, Zhang Z, Qiao H, et al. The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan. J Renin-Angiotensin-Aldosterone Syst. 2016;17(3):1–6.

47. Fava S, Ellard S, Azzopardi J, Hattersley AT. ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care. 2001;24:2115–20.

48. Ghebawi M, Wang K, Viveiros A, Nguyen A, et al. Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulatory of the renin angiotensin system. Circ Res. 2020;126:1456–74. https://doi.org/10.1161/CIRCRESAHA.120.317015.

49. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, et al. Circulating ACE2 activity is increased in patients with type-1 diabetes and vascular complications. J Hypertens. 2012;30(2):375–83.

50. Patel VB, Zhong JC, Grant MB, Oudit GY. Role fo the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313–26.

51. Oudit GY, Imay Y, Kuba K, Scholey JW, et al. The role of ACE2 in pulmonary diseases – relevance for the nephrologist. Nephrol Dial Transplant. 2009;24:1362–5.

52. Khan A, Benthin C, Zeno B, Albertson TE, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234–43.

53. Vinciguerra M, Greco E. Sars-CoV-2 and the black population; ACE2 as shield or blade? Inf Gen Evolution. 2020;84. https://doi.org/10.1016/j.meegid.2020.104361.

54. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671–81. https://doi.org/10.1161/CIRCRESAHA.120.317134.

55. Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in Covid-19 patients. eLife. 2020;9:e57278. https://doi.org/10.7554/eLife.57278.

56. Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-converting enzyme 2 and anti-hypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19). Mayo Clin Proc. 2020;95:1222–30. https://doi.org/10.1016/j.mayocp.2020.03.026.

57. Zhao S, Mukherjee JJ, Sinha B, Gangopadhyay K. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. medRxiv. 2020; his version posted April 28, 2020. https://doi.org/10.1101/2020.04.23.20076661.

58. Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother. 2018;52(11):1143–51.